On the Record · QuidelOrtho
QuidelOrtho acquisitions, on the record
The businesses QuidelOrtho bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Quidel Corporation and Ortho Clinical Diagnostics Holdings plcWord for word“On May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021 (the “BCA”), by and among Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”), QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc. (“U.S. Merger Sub”), and Orca Holdco 2, Inc., Quidel and Ortho consummated a business combination (the “Combinations”) by way of (i) a scheme of arrangement undertaken by Ortho under Part 26 of the U.K. Companies Act 2006 (the “Ortho Scheme”), pursuant to which each issued and outstanding share of Ortho was acquired by a nominee of QuidelOrtho, such that Ortho became a wholly owned subsidiary of QuidelOrtho, and (ii) a merger of U.S. Merger Sub with and into Quidel, with Quidel surviving the merger as a wholly owned subsidiary of QuidelOrtho.” 10-K for 2023 | merger | May 27, 2022 | — |
Joint Business with Grifols Diagnostic Solutions, Inc.Word for word“In connection with the Combinations, we acquired the ongoing collaboration arrangement (the “Joint Business”) between Ortho and Grifols Diagnostic Solutions, Inc. (“Grifols”), under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business.” 10-K for 2023 | acquisition | — | — |
U.S donor screening portfolioWord for word“For example, in February 2024, we initiated a wind-down plan to transition out of the U.S donor screening portfolio, which has a lower growth and margin profile than other parts of our Transfusion Medicine business.” 10-K for 2023 | divestiture | February 2024 | — |
McKellar, San Diego, CA facilityWord for word“Cash used for investing activities was $149.9 million for fiscal year ended 2024, and was primarily related to $195.1 million in purchases of property, equipment, investments and intangibles, partially offset by $9.3 million in net proceeds from the sale of the McKellar, San Diego, CA facility.” 10-K for 2024 | divestiture | — | $9.3 million in net proceeds |
Businesses acquired in the Combinations (Quidel and Ortho)Word for word“Acquisition of businesses, net of cash and restricted cash acquired — — ( 1,511.4 ) Proceeds from government assistance allocated to fixed assets — 13.5 18.4 Purchases of marketable securities ( 7.2 ) ( 60.1 ) ( 63.7 )” 10-K for 2024 | acquisition | — | — |
LEX DiagnosticsWord for word“For example, in June 2025, we announced our intent to acquire LEX Diagnostics.” 10-K for 2025 | agreed acquisition | June 2025 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2021-01-03 | $0 | — |
| 2022-01-02 | $0 | — |
| 2023-01-01 | $1.51 billion | $2.18 billion |
| 2023-12-31 | $0 | — |
| 2024-12-29 | $0 | — |
Deal filings since 2016
- 2026-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-08-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-04-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from QuidelOrtho’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.